M. E. Scheulen
West German Heart and Vascular Center Essen(DE)University of Duisburg-Essen(DE)
Publications by Year
Research Areas
Cancer Treatment and Pharmacology, Colorectal Cancer Treatments and Studies, Testicular diseases and treatments, Cancer therapeutics and mechanisms, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors(2004)870 cited
- → Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer(2005)468 cited
- → A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas(2014)357 cited
- → The Ras-Raf-MEK-ERK Pathway in the Treatment of Cancer(2002)270 cited
- → Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study(2012)252 cited
- → Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study(2009)